BACKGROUND: Valid identification of childhood asthma at the population level for epidemiological purposes remains a challenge. We aimed at validating the Finnish version of the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire based on parental-reported childhood asthma. MATERIALS AND METHODS: The ISAAC questionnaire has been validated against anti-asthmatic medication reimbursement data of the Finnish Social Insurance Institution, being the gold standard, among 2236 5-year-old consecutively born children (1996-2004) carrying human leukocyte antigen (HLA)-conferred susceptibility to type 1 diabetes. Two combined questionnaire questions (any wheezing symptom or use of asthma medication during the preceding 12 months plus ever asthma; any wheezing symptom or use of asthma medication during the preceding 12 months plus ever doctor-diagnosed asthma) were validated against valid reimbursement with purchase of at least one anti-asthmatic medication during a 12-month period. The validity of the questionnaire was estimated as the sensitivity, specificity, positive predictive value, negative predictive value, and Youden's index. RESULTS: The sensitivity 0.98 [95% confidence interval (CI) = 0.92-0.99]; specificity 0.98 (95% CI = 0.97-0.98); negative predictive value 1.00 (95% CI = 1.00-1.00); and Youden's index 0.96 (95% CI = 0.96-0.96) were the same for each of the two sets of combined questions. The positive predictive value for the first combined question was 0.63 (95% CI = 0.55-0.71), while it was 0.64 (95% CI = 0.57-0.72) for the second combined question. CONCLUSION: The Finnish ISAAC questionnaire was highly valid and is an acceptable instrument for the survey of the prevalence of parental-reported childhood asthma for epidemiological purposes.
BACKGROUND: Valid identification of childhood asthma at the population level for epidemiological purposes remains a challenge. We aimed at validating the Finnish version of the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire based on parental-reported childhood asthma. MATERIALS AND METHODS: The ISAAC questionnaire has been validated against anti-asthmatic medication reimbursement data of the Finnish Social Insurance Institution, being the gold standard, among 2236 5-year-old consecutively born children (1996-2004) carrying human leukocyte antigen (HLA)-conferred susceptibility to type 1 diabetes. Two combined questionnaire questions (any wheezing symptom or use of asthma medication during the preceding 12 months plus ever asthma; any wheezing symptom or use of asthma medication during the preceding 12 months plus ever doctor-diagnosed asthma) were validated against valid reimbursement with purchase of at least one anti-asthmatic medication during a 12-month period. The validity of the questionnaire was estimated as the sensitivity, specificity, positive predictive value, negative predictive value, and Youden's index. RESULTS: The sensitivity 0.98 [95% confidence interval (CI) = 0.92-0.99]; specificity 0.98 (95% CI = 0.97-0.98); negative predictive value 1.00 (95% CI = 1.00-1.00); and Youden's index 0.96 (95% CI = 0.96-0.96) were the same for each of the two sets of combined questions. The positive predictive value for the first combined question was 0.63 (95% CI = 0.55-0.71), while it was 0.64 (95% CI = 0.57-0.72) for the second combined question. CONCLUSION: The Finnish ISAAC questionnaire was highly valid and is an acceptable instrument for the survey of the prevalence of parental-reported childhood asthma for epidemiological purposes.
Authors: J Tuokkola; P Luukkainen; H Tapanainen; M Kaila; O Vaarala; M G Kenward; L J Virta; R Veijola; O Simell; J Ilonen; M Knip; S M Virtanen Journal: Eur J Clin Nutr Date: 2016-01-13 Impact factor: 4.016
Authors: Nikos Stratakis; Erika Garcia; Aruna Chandran; Tingju Hsu; Akram Alshawabkeh; Izzuddin M Aris; Judy L Aschner; Carrie Breton; Allison Burbank; Carlos A Camargo; Kecia N Carroll; Zhanghua Chen; Erika C Claud; Dana Dabelea; Anne L Dunlop; Amy J Elliott; Assiamira Ferrara; Jody M Ganiban; James E Gern; Diane R Gold; William A Gower; Irva Hertz-Picciotto; Margaret R Karagas; Catherine J Karr; Barry Lester; Leslie D Leve; Augusto A Litonjua; Yunin Ludena; Cindy T McEvoy; Rachel L Miller; Noel T Mueller; Thomas G O'Connor; Emily Oken; T Michael O'Shea; Frederica Perera; Joseph B Stanford; Katherine Rivera-Spoljaric; Andrew Rundle; Leonardo Trasande; Rosalind J Wright; Yue Zhang; Yeyi Zhu; Kiros Berhane; Frank Gilliland; Lida Chatzi Journal: Epidemiology Date: 2022-01-01 Impact factor: 4.860
Authors: Maria C Magnus; Hein Stigum; Siri E Håberg; Per Nafstad; Stephanie J London; Wenche Nystad Journal: PLoS One Date: 2015-01-30 Impact factor: 3.240
Authors: Adrian J Lowe; Cecilia Ekeus; Lennart Bråbäck; Kristiina Rajaleid; Bertil Forsberg; Anders Hjern Journal: PLoS One Date: 2013-06-28 Impact factor: 3.240
Authors: Sarah J Kotecha; W John Watkins; John Lowe; Raquel Granell; A John Henderson; Sailesh Kotecha Journal: Am J Epidemiol Date: 2019-03-01 Impact factor: 4.897